Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: conix, Foxwoods Man, drkazmd65, The_Q, Charmed7713, Dudmuffin
Search This Board: 
Last Post: 9/22/2020 7:40:15 AM - Followers: 319 - Board type: Free - Posts Today: 1

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4








Products In Development

 

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.

https://www.prnewswire.com/news-releases/biotech-brief-growing-number-of-ongoing-clinical-trials-for-leukemia-aml-brings-new-hope-300827745.html

http://KillCVMShorts.com/faqs

http://KillCVMShorts.com/idmc

http://KillCVMShorts.com

http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

https://seekingalpha.com/instablog/50299941-cvm4life/5309598-setting-record-straight-cel-sci

https://seekingalpha.com/article/4275913-cel-sci-verge-approval#alt2

CVM shares held by iHub investors :

https://docs.google.com/spreadsheets/d/1aU3buYiKiQZDyNPRIBZWGoUk37TrlSjJ/edit#gid=1952396312

https://seekingalpha.com/article/4275913-cel-sci-verge-approval#alt2














 

CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis 09/18/2020 09:00:00 AM
CVM News: CEL-SCI Corporation Issues Letter to Shareholders 09/15/2020 09:15:00 AM
CVM News: CEL-SCI Corporation to Present at H.C. Wainwright 22nd Annual Global Investment Conference 09/11/2020 09:00:00 AM
CVM News: CEL-SCI Corporation Reports Third Quarter Fiscal 2020 Financial Results 08/11/2020 08:30:00 AM
CVM News: Quarterly Report (10-q) 08/10/2020 05:27:09 PM
PostSubject
#30998  Sticky Note Full PR: CEL-SCI Corporation (NYSE American: CVM) announced today BRMachine 05/04/20 07:26:36 AM
#19754  Sticky Note Welcome CVM Newbies sushifishman 04/06/19 08:25:19 AM
#33510   The next short interest report.... sab63090 09/22/20 07:40:15 AM
#33509   So figuring by today’s action we see $12’s boozeman 09/21/20 10:00:17 PM
#33508   I just now looked up the price....the low sab63090 09/21/20 05:37:42 PM
#33506   Yeah, I picked up the purchases (5) were sab63090 09/21/20 05:17:04 PM
#33505   @Robot $12.51? Huh? sushifishman 09/21/20 05:04:05 PM
#33504   An observation from STwits..MikeinSandiego RobotDroid 09/21/20 04:55:16 PM
#33503   Stock seemed to be stopped at prior resistance sab63090 09/21/20 02:00:31 PM
#33502   Just can’t string 2 positive days together. boozeman 09/21/20 01:41:07 PM
#33501   ESMO 2020/Merck sab63090 09/21/20 09:14:57 AM
#33500   Dang, Bio! Great share! fluteman 09/20/20 09:20:31 PM
#33499   Another shot at the short thesis that the Biobonic 09/20/20 09:15:36 PM
#33498   Amethyst Radiology Group in Europe Biobonic 09/20/20 08:29:40 PM
#33497   Recent update to the data in Serbia Biobonic 09/20/20 08:16:18 PM
#33496   Immunotherapy in India Biobonic 09/20/20 06:00:03 PM
#33495   Shorts can still Naked short so even with greens12 09/20/20 01:25:40 PM
#33494   Sushi, I understand that the shorts can depress Hopeforthefuture3 09/20/20 01:01:33 PM
#33492   *Geert Morning Newbies* sushifishman 09/20/20 09:27:27 AM
#33491   @Greens No chance sushifishman 09/19/20 10:32:45 AM
#33490   That's interesting... lightrock 09/19/20 03:03:07 AM
#33489   could be CVM went up big on greens12 09/19/20 02:39:50 AM
#33488   Whatever it is, we may not be the lightrock 09/18/20 08:59:57 PM
#33487   Covering taking place before they get smoked BIGMONEYPLAYA 09/18/20 08:17:17 PM
#33486   What I wonder is who is selling these Trickshot 09/18/20 06:24:02 PM
#33485   Yep check out this trade.... RobotDroid 09/18/20 05:03:59 PM
#33484   Showing $14.75, up .41 in extended trading. zandant 09/18/20 05:03:58 PM
#33483   Just checked after hours steve2150 09/18/20 04:39:23 PM
#33482   So today was quadruple witching day. Monday could staticmirror79 09/18/20 04:29:26 PM
#33480   Fox, life never seems to come in a fluteman 09/18/20 04:25:03 PM
#33479   Wish today was not Friday...would love to see Foxwoods Man 09/18/20 04:21:00 PM
#33478   Droid, "leaks." Hopefully!!!! fluteman 09/18/20 04:19:41 PM
#33477   Wow, went to the store and almost 2 RobotDroid 09/18/20 04:18:12 PM
#33476   News; $CVM CEL-SCI Awarded European Patent for LEAPS whytestocks 09/18/20 04:15:28 PM
#33475   Another 998,200 shares just bought AH!! staticmirror79 09/18/20 04:10:48 PM
#33474   Static, thanks. fluteman 09/18/20 04:10:33 PM
#33473   Flute, staticmirror79 09/18/20 04:08:22 PM
#33472   Static, we've never seen this with CVM, I believe. fluteman 09/18/20 04:04:54 PM
#33471   An 824,962 share trade at the end of staticmirror79 09/18/20 04:04:04 PM
#33470   Cranking at the close Foxwoods Man 09/18/20 03:57:17 PM
#33469   Squeeze!!!!@ BIGMONEYPLAYA 09/18/20 03:46:14 PM
#33468   Droid, better day today. fluteman 09/18/20 03:41:05 PM
#33467   I got lucky, my margin calls forced me RobotDroid 09/18/20 03:38:07 PM
#33466   Perhaps,... but so do I most years,... Cheers! drkazmd65 09/18/20 02:46:10 PM
#33465   But margin makes money baby! Sorry, just had RobotDroid 09/18/20 02:25:09 PM
#33464   Yep - can't borrow anything if you're not drkazmd65 09/18/20 01:44:09 PM
#33463   SHORTS SHARTED THEIR SHORTS! sushifishman 09/18/20 12:07:56 PM
#33462   Mine is fingers and hands, worst is the RobotDroid 09/18/20 11:23:00 AM
#33461   In myself and mother's side of my family mitcheroo 09/18/20 11:07:13 AM
#33460   Curious as to your "gut" impression. Did Trickshot 09/18/20 10:50:26 AM
#33459   Building an IP portfolio also helps with valuation. conix 09/18/20 10:36:43 AM
#33458   Head Bump @ 13 sab63090 09/18/20 10:10:01 AM
PostSubject
Consent Preferences